Intro

ANGel is a hydrogel microparticle based precision formulation and delivery platform. It is designed to integrate multi antibody function (multi mechanism) and a payload driven drug effect (ADC like action) in a single dosage form, while staying compatible with existing therapeutic assets.

Built for localized administration around the tumor site with a sustained release profile, ANGel is developed as a platform that can be standardized, reproduced, and transferred—not a one off formulation.

Lead indication

Triple Negative Breast Cancer (TNBC) is the lead program, with planned expansion into other hard to treat solid tumors.
Proof (2024–2025)

• May 2024 — Founded
• Seed financing secured
• Selected for Korea’s Deep Tech TIPS program + follow on support
• Sep 2025 — KIPA Chairman’s Award (IP Competition)
• Sep 2025 — Pre A financing
• Nov 2025 — Startup Spotlight Finalist (Top 8), BIO Europe

Who we are

We don’t try to improve outcomes by “changing the drug” alone. Instead, we start by engineering the conditions that make combination therapy work—where exposure happens, how long it lasts, and how controllably components act together. ANGel is built as a modular platform, not a single asset product: one technology base designed to be applied repeatedly across multiple programs and multiple indications.

What we build: ANGel platform

ANGel combines antibody surface binding and small molecule payload loading in a modular hydrogel microparticle architecture, designed for localized administration followed by sustained release. Four platform pillars

• Local precision delivery
  Local delivery is the design starting point—built to focus exposure where it matters.
• Sustained release profile
  A sustained exposure profile engineered through formulation and release design.
• Combination by design
  Multi antibody combinations and payload strategies are structured from day one—not added later.
• Mechanism expansion
  Multi mechanism (bispecific inspired) function and ADC like action are implemented through formulation, without new antibody engineering.

Why now

Bispecifics and ADCs are powerful—but they often come with molecular design complexity and manufacturing burden, increasing timelines, cost, and risk. At the same time, the market is shifting toward platform technologies that can be applied directly to existing pipelines to extend performance and lifecycle value.

ANGel is built for that demand: a reformulation first path designed to help partners pursue combination biology and payload effects while leveraging approved / clinically validated assets—and packaging the work in a way that is diligence friendly (specs, reproducibility, CMC documentation).

Open innovation

We treat collaboration as a data driven conversion process, not a one time introduction:
Technical meeting → PoC design → deal structure
As preclinical and GLP datasets mature, collaboration is designed to transition into option / co development / licensing structures aligned to decision ready evidence.